Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Ascletis Pharma-B (01672.HK) Selects ASC30_39 FDC for Clinical Development
Recommend 2 Positive 1 Negative 0 |
||||
|
||||
|
Ascletis Pharma-B (01672.HK) announced that it has selected ASC30_39 FDC, a fixed-dose combination (FDC) of the once-daily oral small molecule GLP-1R agonist ASC30 and the once-daily oral small molecule selective amylin receptor agonist ASC39, for clinical development. The company expects to submit an Investigational New Drug application to the US Food and Drug Administration (FDA) in 3Q26 for ASC30_39 FDC oral tablets for the treatment of obesity. (de/d) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
